top of page
Crystal Salt

Atticus in the News

Atticus Pharma licensed from Zylö Therapeutics the Z-pod® sustained-release technology that originated at Albert Einstein College of Medicine and that was further developed at Zylö.  This platform technology forms the nucleus of Atticus's drug-development programs (see "Pipeline").  Some of the news items listed below were issued by Zylö prior to the license being forged, but relate to Atticus and its various programs.

School Supplies

Atticus accepted into NYU's Endless Frontier Labs [EFL] Mentorship Program

Only 78 of over 1,400 applicants accepted into this prestigious program that is designed to optimize each startup’s chance of scaling into a successful company.


AEA-loaded Z-pods® demonstrated compelling results in various in vivo lupus studies, according to article published in respected peer-reviewed journal 


The Z-pod technology demonstrated significantly better results than AEA without Z-pods.

Holding a Capsule

 $300K NIH Grant Awarded to Advance Anandamide-Loaded Z-pods to Treat Cutaneous Lupus


This grant is in collaboration with Victoria Werth MD, Professor of Dermatology at U. of Pennsylvania, one of the foremost lupus authorities 

Pink Sand

$260,000 NIH Grant Awarded to Create "Topical Viagra®" 


This grant--now 'owned/controlled' by Atticus--is in collaboration with Kelvin Davies Ph.D., Professor of Urology at Einstein College of Medicine

bottom of page